Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Synagis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Synagis was produced by AstraZeneca and AbbVie.

Sobi shows strong growth despite haemophilia competition

Sobi shows strong growth despite haemophilia competition

November also saw Sobi acquire rights to Synagis, the only approved respiratory syncytial virus (RSV) prophylaxis for high-risk infants from AstraZeneca. ... We completed the acquisition of Synagis in late January and are in the process of integrating

US, EU regulators back rapid reviews of AZ’s RSV med

US, EU regulators back rapid reviews of AZ’s RSV med MEDI8897 is a longer-acting follow-up to AZ’s Synagis (palivizumab), which is currently the only drug approved for preventing RSV in high-risk patients. ... Synagis has been a nice earner for AZ, making almost $700m in revenues in 2017, but has started

FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease

FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease Earlier this month, Sobi agreed to acquire the US rights to AstraZeneca’s respiratory syncytial virus (RSV) prevention drug Synagis (palivizumab) in a deal worth $1.5bn. ... Sobi's Guido Oelkers. “Gamifant will add significant strength to Sobi’s

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi s focus on Synagis will enable infants in the US to continue benefiting from this important treatment.”. ... The addition of Synagis will become an important strategic catalyst for Sobi’s future development and will form a powerful platform for

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi AZ sells a prophylactic RSV antibody - Synagis (palivizumab) - which brought in $677m in sales in 2016 despite being reserved for use in high-risk infants.

1 2 3 4 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...
Spotlight interview: 15 minutes on healthcare communications in gene therapy
Gavin Jones, Director of Rare Disease, OPEN Health takes 15 minutes to answer some key questions on healthcare communications in gene therapy...

Infographics